This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berthiaume, M. Articles by Deshaies, Y. Search for Related Content PubMed PubMed Citation Articles by Berthiaume, M. Articles by Deshaies, Y.

Depot-Specific Modulation of Rat Intraabdominal Adipose Tissue Lipid Metabolism by Pharmacological Inhibition of 11ß-Hydroxysteroid Dehydrogenase Type 1

Laval Hospital Research Center and Department of Anatomy and Physiology (M.B., M.L., W.F., Y.G., S.P., J.L., Y.D.) and Division of Kinesiology, Department of Social and Preventive Medicine (D.R.J.), Faculty of Medicine, Laval University, Quebec, Canada G1V 4G5; and Department of External Scientific Affairs (R.T.), Merck Research Laboratories, Rahway, New Jersey 07065

Address all correspondence and requests for reprints to: Dr. Yves Deshaies, Laval Hospital Research Center, Laval Hospital, 2725 Chemin Sainte-Foy Québec, Quebec, Canada G1V 4G5. E-mail: yves.deshaies{at}phs.ulaval.ca.

The metabolic consequences of visceral obesity have been associated with amplification of glucocorticoid action by 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) in adipose tissue. This study aimed to assess in a rat model of diet-induced obesity the effects of pharmacological 11ß-HSD1 inhibition on the morphology and expression of key genes of lipid metabolism in intraabdominal adipose depots. Rats fed a high-sucrose, high-fat diet were treated or not with a specific 11ß-HSD1 inhibitor (compound A, 3 mg/kg·d) for 3 wk. Compound A did not alter food intake or body weight gain but specifically reduced mesenteric adipose weight (–18%) and adipocyte size, without significantly affecting those of epididymal or retroperitoneal depots. In mesenteric fat, the inhibitor decreased (to 25–50% of control) mRNA levels of genes involved in lipid synthesis (FAS, SCD1, DGAT1) and fatty acid cycling (lipolysis/reesterification, ATGL and PEPCK) and increased (30%) the activity of the fatty acid oxidation-promoting enzyme carnitine palmitoyltransferase 1. In striking contrast, in the epididymal depot, 11ß-HSD1 inhibition increased (1.5–5-fold) mRNA levels of those genes related to lipid synthesis/cycling and slightly decreased carnitine palmitoyltransferase 1 activity, whereas gene expression remained unaffected in the retroperitoneal depot. Compound A robustly reduced liver triacylglycerol content and plasma lipids. The study demonstrates that pharmacological inhibition of 11ß-HSD1, at a dose that does not alter food intake, reduces fat accretion specifically in the mesenterical adipose depot, exerts divergent intraabdominal depot-specific effects on genes of lipid metabolism, and reduces steatosis and lipemia.

This article has been cited by other articles:

				S. A. Morgan, M. Sherlock, L. L. Gathercole, G. G. Lavery, C. Lenaghan, I. J. Bujalska, D. Laber, A. Yu, G. Convey, R. Mayers, et al. 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Regulates Glucocorticoid-Induced Insulin Resistance in Skeletal Muscle Diabetes, November 1, 2009; 58(11): 2506 - 2515. [Abstract] [Full Text] [PDF]

				S. Vale Increased Activity of the Oncogenic Fatty Acid Synthase and the Impaired Glucose Uptake in the Metabolic Syndrome Cancer Epidemiol. Biomarkers Prev., July 1, 2009; 18(7): 2151 - 2151. [Full Text] [PDF]

				P. M. Stewart and J. W. Tomlinson Selective Inhibitors of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 for Patients With Metabolic Syndrome: Is the Target Liver, Fat, or Both? Diabetes, January 1, 2009; 58(1): 14 - 15. [Full Text] [PDF]

				M. Laplante, W. T. Festuccia, G. Soucy, P.-G. Blanchard, A. Renaud, J. P. Berger, G. Olivecrona, and Y. Deshaies Tissue-specific postprandial clearance is the major determinant of PPAR{gamma}-induced triglyceride lowering in the rat Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2009; 296(1): R57 - R66. [Abstract] [Full Text] [PDF]

				J. W. Tomlinson, J. Finney, C. Gay, B. A. Hughes, S. V. Hughes, and P. M. Stewart Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5{alpha}-Reductase Activity Diabetes, October 1, 2008; 57(10): 2652 - 2660. [Abstract] [Full Text] [PDF]

				J. W. Tomlinson, J. Finney, B. A. Hughes, S. V. Hughes, and P. M. Stewart Reduced Glucocorticoid Production Rate, Decreased 5{alpha}-Reductase Activity, and Adipose Tissue Insulin Sensitization After Weight Loss Diabetes, June 1, 2008; 57(6): 1536 - 1543. [Abstract] [Full Text] [PDF]

				D. P Macfarlane, S. Forbes, and B. R Walker Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome J. Endocrinol., May 1, 2008; 197(2): 189 - 204. [Abstract] [Full Text] [PDF]

				I. J. Bujalska, K. N. Hewitt, D. Hauton, G. G. Lavery, J. W. Tomlinson, E. A. Walker, and P. M. Stewart Lack of Hexose-6-Phosphate Dehydrogenase Impairs Lipid Mobilization from Mouse Adipose Tissue Endocrinology, May 1, 2008; 149(5): 2584 - 2591. [Abstract] [Full Text] [PDF]

				S. Paglialunga, A. Fisette, Y. Yan, Y. Deshaies, J.-F. Brouillette, M. Pekna, and K. Cianflone Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E521 - E529. [Abstract] [Full Text] [PDF]

				A. M. Nuotio-Antar, D. L. Hachey, and A. H. Hasty Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1517 - E1528. [Abstract] [Full Text] [PDF]

				B. R Walker Glucocorticoids and Cardiovascular Disease Eur. J. Endocrinol., November 1, 2007; 157(5): 545 - 559. [Abstract] [Full Text] [PDF]

				L. L. Gathercole, I. J. Bujalska, P. M. Stewart, and J. W. Tomlinson Glucocorticoid Modulation of Insulin Signaling in Human Subcutaneous Adipose Tissue J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4332 - 4339. [Abstract] [Full Text] [PDF]

				M. Berthiaume, M. Laplante, W. T. Festuccia, K. Cianflone, L. P. Turcotte, D. R. Joanisse, G. Olivecrona, R. Thieringer, and Y. Deshaies 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E1045 - E1052. [Abstract] [Full Text] [PDF]